Her2-specific CAR T cells demonstrated preclinical efficacy in several tumor models, were shown to effectively target Her2-positive glioma cells and glioma stem cells, and to lead to regression of GBM xenografts [31,33,34,35,36]. This evidence concerns the gene ERBB2 and central nervous system cancer.